Cyclezyme (CYCLE) Q2 2026 earnings summary

Executive summary

• Focused on developing enzymatic solutions for PET and polyamide recycling, with significant progress in industrial partnerships and technology optimization during H1 2026.

• Successfully depolymerized industrial textile samples in collaboration with Albany International, demonstrating the potential for circular recycling.

• Expanded enzyme platform to include nylon and polyamide, broadening market opportunities.

• Strengthened financial position post-period with a directed share issue raising approximately 4.0 MSEK.

Financial highlights

• Net sales were 0 KSEK for Q2 2026 (0 KSEK Q2 2025) and 0 KSEK for H1 2026 (150 KSEK H1 2025).

• Operating loss was -735 KSEK for Q2 2026 (-671 KSEK Q2 2025) and -1,560 KSEK for H1 2026 (-1,018 KSEK H1 2025).

• Net loss after tax was -743 KSEK for Q2 2026 (-682 KSEK Q2 2025) and -1,576 KSEK for H1 2026 (-1,041 KSEK H1 2025).

• Cash flow for H1 2026 was -2,138 KSEK (1,084 KSEK H1 2025); cash and cash equivalents at period end were 445 KSEK (2,583 KSEK at 2025 year-end).

• Equity at June 30, 2026, was 6,174 KSEK (7,750 KSEK at 2025 year-end).

Outlook and guidance

• The recent share issue ensures sufficient funding for planned operations over the next 12 months.

• Continued focus on scaling up technology, deepening industrial partnerships, and moving toward commercialization.